In some studies, half of patients stopped taking GLP-1s within a year despite the benefits, citing the expense and side ...

The diabetes medication semaglutide has recently become a trendy weight loss treatment. But like every drug, there are ...

GSK plc GSK announced that the FDA has approved Exdensur (depemokimab-ulaa), an ultra-long-acting IL-5–targeting biologic, as ...

Medically reviewed by Lindsay Cook, PharmD Black seed oil (Nigella sativa), also called black cumin or black caraway, is a herbal ingredient. Some studies suggest it may help with blood sugar, blood ...

(RTTNews) - Fresenius (FRE.DE) announced the launch of its denosumab biosimilars, Conexxence and Bomyntra, in Europe. The biosimilars received approval from the European Commission in July 2025 for ...

INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. today announced the launch of OBODENCE™ (60 mg pre-filled syringe) and XBRYK™ (120 mg vial), denosumab biosimilars referencing Prolia and ...

Following the positive opinions of the Committee for Medicinal Products for Human Use (CHMP), the European Commission has granted marketing authorizations for Teva’s biosimilars PONLIMSI and DEGEVMA ...

Dr. Reddy's Laboratories has achieved a significant regulatory win with the European Commission approving AVT03, its biosimilar for osteoporosis treatment. This authorization extends across all EU ...

TEL AVIV, Israel, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) announced that the European ...

Alvotech (ALVO) on Monday said that the European Commission has approved AVT03 as a biosimilar to Prolia and Xgeva (denosumab). Denosumab is widely used to manage osteoporosis and to prevent ...

The FDA approved Stoboclo and Osenvelt as interchangeable biosimilars for Prolia and XGEVA, enhancing patient access and reducing costs. These biosimilars treat osteoporosis and bone mass loss in ...